<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="Immunosupp. (nâ€‰=â€‰7) ACEI/ARBa(nâ€‰=â€‰6) OACa (nâ€‰=â€‰5) Rituximab (maintenance tx; 500Â mg/dose)" exact="Prednisone" post="(15Â mg/day) IVIGa (2Â g/kg) High dose ASA Lef"/>
 <result pre="mg/day) IVIGa (2Â g/kg) High dose ASA Lef HQ MPSa" exact="Meloxicam" post="Famotidine Folic acid TOC (5 weekly) ETAa (nâ€‰=â€‰2) ABAa"/>
 <result pre="(2Â g/kg) High dose ASA Lef HQ MPSa Meloxicam Famotidine" exact="Folic acid" post="TOC (5 weekly) ETAa (nâ€‰=â€‰2) ABAa (nâ€‰=â€‰1) TOFa (nâ€‰=â€‰1)"/>
 <result pre="anakinra, anti-dsDNA anti-double stranded DNA, ARB antigotensin receptor blocker, ASA" exact="acetylsalicylic acid," post="Ass associated, CAD coronary artery disease, Can canakinumab, CAPS"/>
 <result pre="immunosuppressive, IVIG intravenous immunoglobulin, JAK janus kinase, Lef leflunamide, MMF" exact="mycophenolate mofetil," post="MPS methylprednisolone, MTX methotrexate, mos months, NA not applicable,"/>
 <result pre="patients, Gendelman et al. reported that three were on chronic" exact="hydroxychloroquine" post="(HCQ) and seven were on chronic colchicine treatment [45]."/>
 <result pre="is also observed in severe vasculopathies such as deficiency of" exact="adenosine" post="deaminase 2 [85, 86]. These vascular lesions could be"/>
 <result pre="primary therapeutic options, especially in the treatment of oligoarticular JIA." exact="Ibuprofen" post="has been reported to increase ACE2 expression [111]. And"/>
 <result pre="influenza-associated ARDS [122]. Regarding COVID-19, Wu et al. demonstrated that" exact="methylprednisolone" post="treatment appeared to decrease the risk of death among"/>
 <result pre="et al. observed that early, low-dose, and short-term application of" exact="methylprednisolone" post="was associated with better clinical outcomes while they did"/>
 <result pre="evidence and may enlighten the role of glucocorticoids in COVID-19." exact="Hydroxychloroquine" post="Hydroxychloroquine (HCQ), an antimalarial agent, is the mainstay of"/>
 <result pre="and may enlighten the role of glucocorticoids in COVID-19. Hydroxychloroquine" exact="Hydroxychloroquine" post="(HCQ), an antimalarial agent, is the mainstay of treatment,"/>
 <result pre="associated with viral load reduction with more efficient results when" exact="azithromycin" post="was added [128]. Studies are underway to obtain a"/>
 <result pre="trials planned to test the efficacy of leflunomid, ecluzimab, and" exact="ruxolitinib" post="[148]. The readers are referred to the review by"/>
 <result pre="for disease control during COVID-19 pandemic. And for pain control," exact="acetaminophen" post="could be selected over NSAIDs. Since HCQ is an"/>
 <result pre="RED-ZONE declarationDermatol Ther202010.1111/dth.1347532415727 37.DousaKMMalavadeSSFurinJGripshoverBHatszegiMHojatLSaadeESalataRASARS-CoV-2 infection in a patient on chronic" exact="hydroxychloroquine" post="therapy: implications for prophylaxisIDCases202010.1016/j.idcr.2020.e0077832341910 38.DuretPMSebbagEMallickAGravierSSpielmannLMesserLRecovery from COVID-19 in a"/>
 <result pre="in patients with rheumatic diseases?Ann Rheum Dis202010.1136/annrheumdis-2020-21761532451344 41.KonigMFKimAHScheetzMHGraefERLiewJWSimardJMachadoPMGianfrancescoMYazdanyJLangguthDRobinsonPCAllianceC-GRBaseline use of" exact="hydroxychloroquine" post="in systemic lupus erythematosus does not preclude SARS-CoV-2 infection"/>
 <result pre="14 States, March 1â€&quot;30, 2020MMWR Morb Mortal Wkly Rep20206945846410.15585/mmwr.mm6915e332298251 45.GendelmanOAmitalHBragazziNLWatadAChodickGContinuous" exact="hydroxychloroquine" post="or colchicine therapy does not prevent infection with SARS-CoV-2:"/>
 <result pre="acro-ischemiaZhonghua Xue Ye Xue Za Zhi202041E00610.3760/cma.j.issn.0253-2727.2020.000632220276 85.BatuEDKaradagOTaskiranEZKalyoncuUAksentijevichIAlikasifogluMOzenSA case series of" exact="adenosine" post="deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlationsJ Rheumatol2015421532153410.3899/jrheum.15002426233953"/>
 <result pre="86.OzenSBatuEDTaskiranEZOzkaraHAUnalSGulerayNErdenAKaradagOGumrukFCetinMSonmezHEBilginerYAyvazDCTezcanIA Monogenic disease with a variety of phenotypes: deficiency of" exact="adenosine" post="deaminase 2J Rheumatol20204711712510.3899/jrheum.18138431043544 87.ZhangYXiaoMZhangSXiaPCaoWJiangWChenHDingXZhaoHZhangHWangCZhaoJSunXTianRWuWWuDMaJChenYZhangDXieJYanXZhouXLiuZWangJDuBQinYGaoPQinXXuYZhangWLiTZhangFZhaoYLiYZhangSCoagulopathy and antiphospholipid antibodies in patients"/>
 <result pre="a randomised, double-blind, placebo-controlled, multicentre trialLancet202010.1016/S0140-6736(20)31022-932479790 108.YaoTTQianJDZhuWYWangYWangGQA systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-A possible reference"/>
 <result pre="mellitus at increased risk for COVID-19 infection?Lancet Respir Med20208e2110.1016/S2213-2600(20)30116-832171062 112.DayMCovid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
 <result pre="in Wuhan, ChinaJAMA Intern Med202010.1001/jamainternmed.2020.099432338717 124.WangYJiangWHeQWangCWangBZhouPDongNTongQA retrospective cohort study of" exact="methylprednisolone" post="therapy in severe patients with COVID-19 pneumoniaSignal Transduct Target"/>
 <result pre="pandemicJ Rheumatol202010.3899/jrheum.20036932241801 127.ShahSDasSJainAMisraDPNegiVSA systematic review of the prophylactic role of" exact="chloroquine" post="and hydroxychloroquine in coronavirus disease-19 (COVID-19)Int J Rheum Dis202010.1111/1756-185X.1384232281213"/>
 <result pre="127.ShahSDasSJainAMisraDPNegiVSA systematic review of the prophylactic role of chloroquine and" exact="hydroxychloroquine" post="in coronavirus disease-19 (COVID-19)Int J Rheum Dis202010.1111/1756-185X.1384232281213 128.GautretPLagierJCParolaPHoangVTMeddebLMailheMDoudierBCourjonJGiordanengoVVieiraVEDupontHTHonoreSColsonPChabriereELa ScolaBRolainJMBrouquiPRaoultDHydroxychloroquine"/>
 <result pre="in coronavirus disease-19 (COVID-19)Int J Rheum Dis202010.1111/1756-185X.1384232281213 128.GautretPLagierJCParolaPHoangVTMeddebLMailheMDoudierBCourjonJGiordanengoVVieiraVEDupontHTHonoreSColsonPChabriereELa ScolaBRolainJMBrouquiPRaoultDHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="Antimicrob Agents202010.1016/j.ijantimicag.2020.10594932205204 129.MarmorMFKellnerULaiTYMellesRBMielerWFcollab: American Academy of ORecommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology20161231386139410.1016/j.ophtha.2016.01.05826992838 130.O'LaughlinJPMehtaPHWongBCLife threatening severe QTc"/>
 <result pre="129.MarmorMFKellnerULaiTYMellesRBMielerWFcollab: American Academy of ORecommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology20161231386139410.1016/j.ophtha.2016.01.05826992838 130.O'LaughlinJPMehtaPHWongBCLife threatening severe QTc prolongation in"/>
 <result pre="131.MasonJWAntimicrobials and QT prolongationJ Antimicrob Chemother2017721272127410.1093/jac/dkw59128160473 132.SalehMGabrielsJChangDKimBSMansoorAMahmoodEMakkerPIsmailHGoldnerBWillnerJBeldnerSMitraRJohnRChinitzJSkipitarisNMountantonakisSEpsteinLMThe effect of chloroquine," exact="hydroxychloroquine" post="and azithromycin on the corrected QT interval in patients"/>
 <result pre="QT prolongationJ Antimicrob Chemother2017721272127410.1093/jac/dkw59128160473 132.SalehMGabrielsJChangDKimBSMansoorAMahmoodEMakkerPIsmailHGoldnerBWillnerJBeldnerSMitraRJohnRChinitzJSkipitarisNMountantonakisSEpsteinLMThe effect of chloroquine, hydroxychloroquine and" exact="azithromycin" post="on the corrected QT interval in patients with SARS-CoV-2"/>
</results>
